Applications of miRNA technology for atherosclerosis

Current Atherosclerosis Reports

Volumn 16, Issue 2, 2014, Pages

  Toba, Hiroe ^a,b,c,e   Cortez, Dolores ^e   Lindsey, Merry L ^b,c,d,e   Chilton, Robert J ^e  

^a KYOTO PHARMACEUTICAL UNIVERSITY   (Japan)

^b UNIVERSITY OF MISSISSIPPI MEDICAL CENTER   (United States)

^c UNIVERSITY OF MISSISSIPPI SCHOOL OF MEDICINE   (United States)

^d G V SONNY MONTGOMERY VETERANS AFFAIRS MEDICAL CENTER   (United States)

^e UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

Atherosclerosis; Cardiovascular disease; Diabetes; Hyperlipidemia; Insulin resistance; Matrix metalloproteinase; Metabolics; MicroRNA; Obesity; Proteomics

Indexed keywords

BIOLOGICAL MARKER; MICRORNA; MICRORNA 100; MICRORNA 126; MICRORNA 127; MICRORNA 133A; MICRORNA 133B; MICRORNA 145; MICRORNA 155; MICRORNA 17; MICRORNA 92A; UNCLASSIFIED DRUG;

ATHEROSCLEROSIS; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DISEASE COURSE; DYSLIPIDEMIA; GENE EXPRESSION REGULATION; GENE REPRESSION; GENE SILENCING; GENETIC ENGINEERING AND GENE TECHNOLOGY; HUMAN; INSULIN RESISTANCE; OBESITY; REVIEW; RNA DEGRADATION; RNA METABOLISM; TRANSLATION INITIATION; ANIMAL; GENETICS; INFLAMMATION; METABOLISM; PHYSIOLOGY; SIGNAL TRANSDUCTION;

ANIMALS; ATHEROSCLEROSIS; BIOLOGICAL MARKERS; GENE EXPRESSION REGULATION; HUMANS; INFLAMMATION; MICRORNAS; SIGNAL TRANSDUCTION;

EID: 84891517825     PISSN: 15233804     EISSN: 15346242     Source Type: Journal    
DOI: 10.1007/s11883-013-0386-9     Document Type: Review

References (20)

1. Lee RC, Feinbaum RL, Ambros V. The c. Elegans heterochronic gene lin-4 encodes small rnas with antisense complementarity to lin-14. Cell. 1993;75(5):843-54. (Pubitemid 24014542)
2. • van Rooij E, Purcell AL, Levin AA. Developing microrna therapeutics. Circ Res. 2012;110(3):496-507. Describes potential for using miRNA for therapeutics.
3. • Raitoharju E, Lyytikainen LP, Levula M, Oksala N, Mennander A, Tarkka M, et al. Mir-21, mir-210, mir-34a, and mir-146a/b are up-regulated in human atherosclerotic plaques in the tampere vascular study. Atherosclerosis. 2011;219(1):211-7. Identifies particular miRNAs increased in human atherosclerosis.
4. Caolo V, Schulten HM, Zhuang ZW, Murakami M, Wagenaar A, Verbruggen S, et al. Soluble jagged-1 inhibits neointima formation by attenuating notch-herp2 signaling. Arterioscler Thromb Vasc Biol. 2011;31(5):1059-65.
5. Ma L, Yang J, Runesha HB, Tanaka T, Ferrucci L, Bandinelli S, et al. Genome-wide association analysis of total cholesterol and high-density lipoprotein cholesterol levels using the framingham heart study data. BMC Med Genet. 2010;11:55.
6. Kjolby M, Andersen OM, Breiderhoff T, Fjorback AW, Pedersen KM, Madsen P, et al. Sort1, encoded by the cardiovascular risk locus 1p13.3, is a regulator of hepatic lipoprotein export. Cell Metab. 2010;12(3):213-23.
7. • Chen KC, Wang YS, Hu CY, Chang WC, Liao YC, Dai CY, et al. Oxldl up-regulates microrna-29b, leading to epigenetic modifications of mmp-2/mmp-9 genes: A novel mechanism for cardiovascular diseases. Faseb J. 2011;25(5):1718-28. Identified miRNA-29b as modifying MMP activity.
8. Yuan M, Zhan Q, Duan X, Song B, Zeng S, Chen X, et al. A functional polymorphism at mir-491-5p binding site in the 3′-utr of mmp-9 gene confers increased risk for atherosclerotic cerebral infarction in a chinese population. Atherosclerosis. 2013;226(2):447-52.
9. • Cipollone F, Felicioni L, Sarzani R, Ucchino S, Spigonardo F, Mandolini C, et al. A unique microrna signature associated with plaque instability in humans. Stroke. 2011;42(9):2556-63. Identified the miRNA signature that yields unstable plaque.
10. Fichtlscherer S, De Rosa S, Fox H, Schwietz T, Fischer A, Liebetrau C, et al. Circulating micrornas in patients with coronary artery disease. Circ Res. 2010;107(5):677-84.
11. Wang D, Xia M, Yan X, Li D, Wang L, Xu Y, et al. Gut microbiota metabolism of anthocyanin promotes reverse cholesterol transport in mice via repressing mirna-10b. Circ Res. 2012;111(8):967-81.
12. Horie T, Baba O, Kuwabara Y, Chujo Y, Watanabe S, Kinoshita M, et al. Microrna-33 deficiency reduces the progression of atherosclerotic plaque in apoe-/-mice. J Am Heart Assoc. 2012;1(6):e003376.
13. Estruch R, Ros E, Salas-Salvado J, Covas MI, Corella D, Aros F, et al. Primary prevention of cardiovascular disease with a mediterranean diet. N Engl J Med. 2013;368(14):1279-90.
14. Tang WH, Wang Z, Levison BS, Koeth RA, Britt EB, Fu X, et al. Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk. N Engl J Med. 2013;368(17):1575-84.
15. Wang Z, Klipfell E, Bennett BJ, Koeth R, Levison BS, Dugar B, et al. Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease. Nature. 2011;472(7341):57-63. doi:10.1038/nature09922.
16. Wang D, Zou T, Yang Y, Yan X, Ling W. Cyanidin-3-o-beta-glucoside with the aid of its metabolite protocatechuic acid, reduces monocyte infiltration in apolipoprotein e-deficient mice. Biochem Pharmacol. 2011;82(7):713-9.
17. Wang D, Wei X, Yan X, Jin T, Ling W. Protocatechuic acid, a metabolite of anthocyanins, inhibits monocyte adhesion and reduces atherosclerosis in apolipoprotein e-deficient mice. J Agric Food Chem. 2010;58(24):12722-8.
18. Herrera BM, Lockstone HE, Taylor JM, Ria M, Barrett A, Collins S, et al. Global microrna expression profiles in insulin target tissues in a spontaneous rat model of type 2 diabetes. Diabetologia. 2010;53(6):1099-109.
19. • Jordan SD, Kruger M, Willmes DM, Redemann N, Wunderlich FT, Bronneke HS, et al. Obesity-induced overexpression of mirna-143 inhibits insulin-stimulated akt activation and impairs glucose metabolism. Nat Cell Biol. 2011;13(4):434 - 46. Identifies miRNA-143 as being increased in impaired glucose metabolism.
20. Meerson A, Traurig M, Ossowski V, Fleming JM, Mullins M, Baier LJ. Human adipose microrna-221 is upregulated in obesity and affects fat metabolism downstream of leptin and tnf-alpha. Diabetologia. 2013;56(9):1971-9.